Please assess the completion status of the following clinical trial:

Trial Title: A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Written consent on an Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) approved informed consent form before any study specific evaluation~2. Males and Females between 18 and 70 years of age~3. Body Mass Index (BMI): 18-39 kg/m\^2~4. Having IBS-C or IBS-D as defined by Rome IV\* including Subtype Classification as defined in Table 2~   \* Recurrent abdominal pain on average, at least 1 day/week in the last 3 months associated with two or more of the following criteria:~  * Related to defecation~  * Associated with a change in frequency of stool~  * Associated with a change in form (appearance) of stool~5. Have a moderate or severe IBS symptom severity score (\> 175) as defined by IBS-SSS~Table 2:~IBS -C Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of \> 3.0 on a 0 to 10-point scale And Stool Frequency: more than 25% of bowel movements with a consistency of Type 1 or Type 2 Bristol stool chart and less than 25% of bowel movements with Bristol stool form Type 6 or Type 7. Participants must have fewer than 3 complete spontaneous bowel movements (CSBMs) within a one week period (7 days)~IBS-D Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of \> 3.0 on a 0 to 10-point scale And Stool Consistency: more than 25% of bowel movements with a consistency of Type 6 or Type 7 Bristol stool chart and less than 25% of bowel movements with Bristol stool form Type 1 or Type 2.Participants must have at least one Type 6 or Type 7 bowel movements on at least four days within a one week period (7 days).~Exclusion Criteria:~1. Males or females \<18 and \>70 years of age~2. Have a IBS symptom severity score \< 175 as defined by IBS-SSS~3. BMI: \<18 or \>39 kg/m\^2~4. Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrine, immunological, metabolic or any condition which contraindicates, in the investigators' judgment, entry to the study)~5. Confirmed clinical diagnosis of bile acid malabsorption and / or on medication for bile acid malabsorption~6. Individuals who, in the opinion of the investigator, are poor attendees or unlikely for any reason to be able to comply with the study requirements~7. Participant is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or participant is receiving other investigational agent(s)~8. Have a malignant disease or any concomitant end-stage organ disease.~9. Females who are pregnant or breast feeding~10. Refusal to use acceptable methods of birth control (true abstinence, sterilisation, birth control pills, injections or contraceptive implants) for fertile participants (females) while on treatment and following completion of 2 menstrual cycles/ months after the last dose of study treatment. For Males, a barrier method of birth control from randomisation until the Follow-Up visit~11. Use of antibiotics within 1 month of screening~12. Use of systemic steroids within the last month~13. Change in dose or introduction of an antipsychotic within the last month~14. Have suffered from a major psychiatric disorder~15. Clinically diagnosed Lactose intolerance~16. Clinically diagnosed Coeliac disease~17. Change of diet e.g. FODMAP, gluten-free within last 3 months~18. Those \> 50 will be excluded if their diagnosis of IBS is recent (\<12 months) and if they have not had a sigmoidoscopy or colonoscopy within previous 5 years.~19. Any gastrointestinal-related abdominal surgery other than hernia repair or appendectomy~20. Participants taking prucalopride~21. Other investigational procedures while participating in this study are excluded~22. Known HIV infection, or hepatitis A, B, or C active infection~23. Participants with abnormal laboratory values at screening deemed by the investigator to be clinically significant~24. Participants who have taken commercially available probiotics within the last month (30 days prior to randomization)~25. Participants with known or suspected hereditary fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltose insufficiency~26. Participants taking guanylate cyclase agonists, such as linaclotide and lubiprostone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cohort C: Blautix (Type: EXPERIMENTAL): Participants diagnosed with Irritable bowel syndrome subtype C (IBS-C) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10\^10 to10\^11 most probable number (MPN).
- Cohort C: Placebo (Type: PLACEBO_COMPARATOR): Participants diagnosed with IBS-C received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
- Cohort D: Blautix (Type: EXPERIMENTAL): Participants diagnosed with Irritable bowel syndrome subtype D (IBS-D) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10\^10 to10\^11 MPN.
- Cohort D Placebo (Type: PLACEBO_COMPARATOR): Participants diagnosed with IBS-D received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).